CliffBio
small molecule

ALTOPREV

LOVASTATIN

Loss of exclusivity—loss of exclusivity
CompanyAZURITY PHARMACEUTICALS SWITZERLAND GMBH

Drug detail

Brand nameALTOPREV
Active ingredientLOVASTATIN
Strength10MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2002
Marketing statusDISCN

More from AZURITY PHARMACEUTICALS SWITZERLAND GMBH

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ALTOPREV patent cliff — loss of exclusivity — | CliffBio